Clinical Trials

Before any new treatment can be approved, it must first go through a prescribed series of clinical trials to assess first its safety and then its efficacy.

pipetting samples

 

The mutually beneficial relationship between patients and research at the Anne Rowling Clinic provides an ideal platform to conduct clinical trials.

Please note that participation in any trial is entirely voluntary.

 

 

Clinical Trials Enrolling Now

  • RESTART - REstart or STop Antithrombotics Randomised Trial

RESTART is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet medication) for the prevention of vaso-occlusive disease before the haemorrhage.

For more information see www.restarttrial.org/default.html.

  • Multiple Sclerosis - Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART)

This trial, run jointly with University College London, will assess the effect of three drugs (ibudilast, riluzole and amiloride) versus placebo in secondary progressive MS. THIS TRIAL IS NOW FULLY ENROLLED.

ClinicalTrials.gov Identifier: NCT01910259

For more details, see www.ms-smart.org

Read more in our news article (1st April 2015): New clinical trial in multiple sclerosis


Fully Enrolled Clinical Trials  / Recent Clinical Trials

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS (ASCEND in SPMS)

This study is investigating whether treatment with a drug called Natalizumab (Tysabri) slows down the accumulation of disability in people with secondary progressive MS. THIS STUDY IS FULLY ENROLLED.

ClinicalTrials.gov Identifier: NCT01416181

Contact: neurologyclinicaltrials@biogenidec.com

 

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis (DECIDE)

This three-year study will try to determine if a drug called Daclizumab is more effective in the treatment of MS than a currently available treatment. It also aims to provide researchers with more information about the safety of the long-term treatment with the drug in people with MS. THIS STUDY IS FULLY ENROLLED.

ClinicalTrials.gov Identifier: NCT01064401